Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.

ABSTRACT:

Importance

Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM for DCIS are lacking.

Objective

To compare PROs at baseline and over time in patients with low-risk DCIS randomized to receive either AM or GCC.

Design, setting, and participants

This prespecified secondary outcome analysis used prospectively collected validated questionnaires at baseline, 6 months, 1 year, and 2 years from participants enrolled from June 2017 to January 2023 in the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) study for low-risk DCIS, w

SUBMITTER: Partridge AH 

PROVIDER: S-EPMC11908405 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature